Key Takeaways and Closing Thoughts on CIDP Diagnosis and Treatment

In the final episode, "Key Takeaways and Closing Thoughts on CIDP Diagnosis and Treatment," the panelists explore the most important lessons and forward-looking perspectives from their comprehensive discussion on CIDP. Reflecting on the treatment landscape, one expert expresses enthusiasm for the progress made beyond the era when managing corticosteroid side effects dominated clinical practice, while acknowledging that immunoglobulin therapy, though highly effective, does not work for all patients. The panel shares collective optimism about recently approved and pipeline therapies that offer improved efficacy and tolerability for patients who do not respond adequately to existing treatments.

On the topic of diagnosis, a panelist reiterates that early and accurate identification of CIDP remains paramount, cautioning that both overdiagnosis and underdiagnosis continue to pose significant clinical challenges. A short three-month trial of immunotherapy is offered as a practical diagnostic tool in cases of suspected acquired demyelination that do not fully meet CIDP criteria, with the important caveat that objective outcome measures — rather than subjective patient-reported improvement alone — must guide the assessment of treatment response. Patients who improve subjectively but show no objective change should not be continued on therapy indefinitely.

The panel also emphasizes that a lack of response to evidence-based treatment should prompt reassessment of the diagnosis before escalating therapy. Serum immunofixation is highlighted as an essential test in all patients with suspected CIDP, given that paraproteinemic neuropathies, including those associated with myeloma and other malignancies, can closely mimic the condition and carry serious consequences if the underlying diagnosis is missed or delayed. The episode closes with a reminder that just as treatment response supports a CIDP diagnosis, treatment failure should call it into question — a principle panelists identify as a critical and sometimes overlooked aspect of responsible clinical practice.

Thank you for watching this Peer Exchange series on CIDP. Please subscribe to our newsletter for information on upcoming video series.